Latest Cash Runway News

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

InFocus Group Holdings has launched Codexa, a proprietary sweepstakes casino platform targeting the US market, and secured an expanded contract for its Prodigy9 subsidiary in Thailand, while navigating cash flow pressures amid ongoing R&D investment.

Alligator Energy has moved into uranium extraction at its Samphire project, reporting initial Field Recovery Trial results that meet or exceed expectations and launching a Bankable Feasibility Study to underpin development.

Megado Minerals confirms robust copper and silver grades over 7km at its Iberian Copper Project and secures a five-year option for the high-grade Alpartir Silver-Copper-Antimony Project, positioning itself for a drilling campaign backed by Spanish government funding.

Aurora Labs has made significant strides in commercial propulsion delivery and deepened its partnership with European defence giant MBDA, while scaling manufacturing capabilities and reinforcing its Board with defence expertise.

Bubalus Resources reports encouraging gold intercepts from maiden Avon Plains drilling while streamlining its portfolio to prioritise Victorian assets and critical minerals projects. The company maintains a solid $3 million cash buffer amid cost cuts and plans multiple exploration campaigns in the coming quarters.

Deep Yellow Limited’s latest drilling at Namibia’s Tinkas Prospect confirms substantial uranium mineralisation, while a seismic survey in Australia’s Alligator River Project sharpens drill targeting for 2026.

ION Video has trimmed its monthly cash burn to $148,000, beating management’s forecast, and expects to maintain sufficient funding until at least mid-2027. Meanwhile, early-stage discussions with tech giants Meta and Alphabet remain active but non-binding.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing of its investigational drug PYC-001 for Autosomal Dominant Optic Atrophy from single to multiple doses, marking a key step in its clinical development.

Zoono Group has boosted its cash receipts by NZ$333,000 this quarter, driven by initial orders worth NZ$585,000 in its fresh food shelf-life extension sector. Despite operating losses, the company expects to sustain operations through signed contracts and inventory.

Mindax Limited pushes forward its vision for a Mid-West iron ore processing hub with metallurgical testing and strategic investments, while managing a cash runway under one quarter and preparing further capital raises.